307
Participants
Start Date
March 31, 2009
Primary Completion Date
July 31, 2011
Study Completion Date
February 28, 2013
Sorafenib (Nexavar, BAY43-9006)
800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. \[twice daily\], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
Placebo
4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
Changhua Christian Hospital, Changhua
Bruxelles - Brussel
Vienna
Bruxelles - Brussel
Bruxelles - Brussel
Camperdown
St Leonards
Leuven
Melbourne
Heidelberg
Clayton
Liège
Greenslopes
Nedlands
Innsbruck
Taipei
New York
Turin
Taipei
Marseille
Berlin
Córdoba
A Coruña
Santiago de Compostela
Milan
Milan
Hamburg
Richmond
Madrid
Madrid
Fundación Hospital Alcorcón, Alcorcón
Hanover
Orlando
Hospital Central de Asturias, Oviedo
Miami
Padua
Verona
San Cristóbal de La Laguna
Bologna
Hospital Universitario Virgen del Rocío, Seville
Cleveland
Essen
Essen
Valencia
Münster
Detroit
Cruces/Barakaldo
Vandœuvre-lès-Nancy
Mainz
Abbott Northwestern Hospital, Minneapolis
Pisa
Lille
Frankfurt am Main
St Louis
Homburg
Lyon
Heidelberg
Lyon
Bari
Tübingen
Paris
Paris
Freiburg im Breisgau
Napoli
München
Palermo
Erlangen
La Jolla
Regensburg
Créteil
San Francisco
Villejuif
Villejuif
Portland
Seattle
Beijing
Beijing
Singapore
Singapore
Shanghai
Shanghai
Guangzhou
Guangzhou
Xi'an
Los Angeles
Gainesville
Atlanta
Ann Arbor
Columbus
Seattle
Calgary
Halifax
Toronto
Jena
Rome
Rome
Daegu
Gyeonggi-do
Seoul
Seoul
Seoul
Gangnam Severance Hospital, Yonsei University, Seoul
Badalona
Sabadell
Barcelona
Alicante
Barcelona
Lead Sponsor
Bayer
INDUSTRY